The European Randomized Study of Screening for Prostate Cancer (ERSPC)

Schröder, Fritz H.; Bangma, Chris H.

doi:10.1111/j.1464-410x.1997.tb00804.x

Cited by 112 publications

(64 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, if IPSS scores of 0-7 and 8-35 are regarded as asymptomic and symptomatic, respectively, our results suggest that symptomatic men are not at higher risk of early prostate cancer than asymptomatic men of the same age group. The higher mean PSA level in symptomatic men in the present study is probably attributable to the involvement of other factors such as benign prostatic hyperplasia (BPH) rather than cancer itself, 12,13 because the mean prostate volume in symptomatic men was larger than that in asymptomatic men, although the difference was not significant.…”

Section: Discussioncontrasting

confidence: 53%

“…These biopsy rates were not significantly different between the two groups. Of the 178 men who underwent biopsy, 117 (66%) had low symptom scores (0-7), 50 (28%) had moderate scores (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19), and 11 (6%) had severe scores (20-35). There was no significant intergroup difference in mean age in the men who underwent biopsy.…”

Section: Resultsmentioning

confidence: 99%

“…This might be because the number of men who had abnormally high IPSS scores of 20-35 was as low as 11 (6%) out of the total of 178 who were biopsied and, therefore, prostate volume did not differ appreciably between the 0-7 and 8-35 IPSS groups. In the report by Porter and Kim, 14 41, 32 and 27% of men had low (0-7), moderate (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)) and severe (20-35) scores, respectively. There might also be a point of difference between races.…”

Section: Discussionmentioning

confidence: 95%

See 2 more Smart Citations

Lower urinary tract symptoms and risk of prostate cancer in Japanese men

et al. 2006

View full text Add to dashboard Cite

Aim:Our aim was to investigate whether or not men with lower urinary tract symptoms are at increased risk of prostate cancer. Methods: A total of 3511 men aged 50-79 years who underwent mass screening for prostate cancer between 2002 and 2004 for the first time, and completed the International Prostate Symptom Score (IPSS) questionnaire at the time of the prostate specific antigen (PSA) test, were enrolled in the present study. All men with PSA values greater than 4.0 ng/mL were advised and encouraged to undergo transrectal systematic sextant biopsy. The number of cancers subsequently detected was compared between men with IPSS scores of 0-7 and 8-35. Results: Of the 3511 men, 219 (6.2%) had PSA values greater than 4 ng/mL, 178 (5.1%) underwent biopsy, and 51 (1.5%) were found to have prostate cancer. Although the PSA positivity rate for men with IPSS scores of 8-35 was significantly higher than that in the 0-7 group, there were no significant intergroup differences in the cancer detection rates for biopsied men and for total screened subjects. Multivariate logistic regression analysis revealed that prostate volume was the dominant predictor for the detection of prostate cancer, followed by PSA level, but the IPSS made no significant contribution. No significant difference was noted in the IPSS scores between men with cancer and the others of the same age group. Conclusions: Symptomatic Japanese men are not at higher risk of prostate cancer despite their higher PSA values compared with asymptomatic men of the same age group.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 95%

See 1 more Smart Citation

Lower urinary tract symptoms and risk of prostate cancer in Japanese men

et al. 2006

View full text Add to dashboard Cite

show abstract

“…1 Transrectal ultrasound (TRUS)-guided prostate needle biopsy (PB) is a simple and reliable technique to obtain prostatic tissue for histological evaluation. [2][3][4] Most men with elevated PSA or abnormal digital rectal examination (DRE) undergo TRUS-PB.…”

Section: Introductionmentioning

confidence: 99%

Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study

Manoharan

Ayyathurai

Nieder

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Hemospermia is known to be associated with transrectal ultrasound-guided prostate biopsy (TRUS-PB). The true incidence of hemospermia, its duration and implications are not well established. We performed a prospective observational study involving patients undergoing TRUS-PB for suspected prostate cancer at our institution. Sixty-three eligible men were included in the study. Most men (84%) undergoing TRUS-PB, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety. The mean duration of hemospermia was 3.5 (71.7) weeks. The number of ejaculations before the complete resolution of hemospermia was 8 (76.7). None of the clinical and pathological factors was a significant predictor of the duration of hemospermia. Patients should be adequately counseled before TRUS-PB to avoid undue anxiety and alterations in sexual activity.

show abstract

“…3,4 Two large randomized screening trials, the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and the European Randomized Study of Screening for Prostate Cancer (ERSPC) are underway, but the results may not be known for several years. 5,6 In view of this uncertainty, varying guidelines exist regarding when or if to screen for PC. 7,8 In the absence of data from randomized trials, case-control studies in which PC screening history of men who died of PC (case subjects) is compared to that of surviving men (control subjects), can be used to estimate the effectiveness of PC screening.…”

Section: Introductionmentioning

confidence: 99%

Population-Based Case-Control Study of PSA and DRE Screening on Prostate Cancer Mortality

Bergstralh

Roberts

Farmer

et al. 2007

Urology

View full text Add to dashboard Cite

Objectives-The efficacy of screening for prostate cancer (PC) with digital rectal exam (DRE) and prostate specific antigen (PSA) has not been proven in randomized clinical trials. In an earlier casecontrol study we found that DRE may reduce PC mortality. This case-control study assesses the association between both PSA and DRE testing and prostate cancer mortality. Methods-Case subjects included 74 Olmsted County residents who died from 1992-2005 with PCas the underlying cause of death. From one to three community control subjects (alive at time of case's death) were matched to each case. Medical records were reviewed to identify DRE's and PSA determinations performed from 0 to 5 years before the date the case was diagnosed (index date). Tests performed in the absence of symptoms were considered to be "screening." Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association of screening (defined in multiple ways) and PC mortality.Results-From 1-5 years before the index date, control subjects were more likely than case subjects to have had a prior screening PSA or DRE (81.3% vs. 60.8%, p = 0.0005). The unadjusted OR (95% CI) associated with a prior screening PSA or DRE was 0.34 (0.18, 0.63), while the OR adjusted for potential confounders was 0.35 (0.17, 0.71). PSA testing was frequently done in conjunction with DRE, making evaluation of individual effects difficult.Conclusion-This case-control study suggests a potential benefit of screening by PSA and/or DRE on prostate cancer mortality.

show abstract

The European Randomized Study of Screening for Prostate Cancer (ERSPC)

Cited by 112 publications

References 3 publications

Lower urinary tract symptoms and risk of prostate cancer in Japanese men

Lower urinary tract symptoms and risk of prostate cancer in Japanese men

Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study

Population-Based Case-Control Study of PSA and DRE Screening on Prostate Cancer Mortality

Contact Info

Product

Resources

About